ESMO Asia 2020

Medical Materials

Agenda

Coming soon

06:45 PM

Duration 95mins Channel 4

Efficacy and safety of ▼entrectinib in an Asian population with NTRK fusion-positive (fp) solid tumours or ROS1-fp NSCLC

Tan D, Ahn M-J, Chiu C-H, Ohe Y, Loong HHF, Chee CE, Kim S-W, Takeda M, Li YC, Cheng ACK, Hida T, Kim D-W, Nogami N, Su W-C, Tanaka H, Osborne S, Freund R, Chen D, Seto T

Oncology | Solid Tumours

Add to calendar

07:25 PM

Duration 5mins Channel 2

IMpassion031: Results from a Phase III study of neoadjuvant atezolizumab▼ + chemotherapy in early triple-negative breast cancer (TNBC)

Saji S, Mittendorf EA, Harbeck N, Zhang A, Barrios C, Hegg R, Koehler A, Sohn JH, Iwata H, Telli ML, Ferrario C, Punie K, Penault-Llorca F, Patel S, Chui S, Liste Hermoso M, Nguyen Duc A, Maiya M, Molinero L, Jung KH

Oncology | Breast Cancer

Add to calendar

07:30 PM

Duration 5mins Channel 2

IMpassion130: Final OS analysis from the pivotal Phase III study of atezolizumab▼ + nab-paclitaxel vs placebo + nab-paclitaxel in patients with previously untreated locally advanced or metastatic triple-negative breast cancer

Iwata H, Emens L, Adams S, Barrios C, Dieras V, Loi S, Rugo H, Schneeweiss A, Winer E, Patel S, Chui S, Henschel V, Swat A, Kaul M, Molinero L, Schmid P

Oncology | Breast Cancer

Add to calendar

04:07 PM

Duration 80mins Channel 1

Final Efficacy Results From IMpower132: First-Line ▼Atezolizumab + Chemotherapy in Patients With Stage IV Non-Squamous NSCLC

Nishio M, Barlesi F, Ball S, Bordoni R, Cobo M, Dubray Longeras P, Goldschmidt J, Novello S, Orlandi F, Sanborn RE, Szalai Z, Ursol G, Mendus D, Wang L, Wen X, McCleland M, Hoang T, Phan S, Socinski MA

Oncology | Lung Cancer

Add to calendar

External site

ESMO Asia 2020